RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$40.21-5.65%
Price as of Jul 20, 2026
RAPP financials
Rapport Therapeutics, Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $1.0M | $839.0K | $112.0K | $15.0K |
| Gross profit | -$1.0M | -$839.0K | -$112.0K | -$15.0K |
| Operating expenses | $125.1M | $82.2M | $36.1M | $10.4M |
| Operating income | -$125.1M | -$83.1M | -$36.2M | -$10.4M |
| Net income | -$111.5M | -$78.3M | -$34.8M | -$10.7M |
| EBITDA | -$124.1M | -$77.5M | -$34.7M | -$10.4M |
| Basic EPS | $-2.86 | $-3.78 | $-0.95 | $-0.29 |
| Diluted EPS | $-2.86 | $-3.78 | $-0.95 | $-0.29 |
| Balance sheet | ||||
| Cash & equivalents | $52.6M | $56.8M | $70.2M | $31.2M |
| Total assets | $512.4M | $314.9M | $155.4M | $31.6M |
| Total liabilities | $27.8M | $9.5M | $181.1M | $12.1M |
| Stockholders’ equity | $484.7M | $305.4M | -$25.6M | $19.5M |
| Total debt | $11.5M | $1.5M | $2.1M | $10.4M |
| Net debt | -$41.2M | -$55.3M | -$68.0M | -$20.7M |
| Cash flow | ||||
| Operating cash flow | -$87.5M | -$64.8M | -$27.2M | -$3.2M |
| Capital expenditure | -$616.0K | -$2.4M | -$1.6M | -$284.0K |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M | -$3.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$1.0K | $0.00 | -$4.0K | $0.00 |